HK1146299A1 - Promoter for introducing gene into lymphocyte or blood cell and application thereof - Google Patents

Promoter for introducing gene into lymphocyte or blood cell and application thereof

Info

Publication number
HK1146299A1
HK1146299A1 HK11100473.3A HK11100473A HK1146299A1 HK 1146299 A1 HK1146299 A1 HK 1146299A1 HK 11100473 A HK11100473 A HK 11100473A HK 1146299 A1 HK1146299 A1 HK 1146299A1
Authority
HK
Hong Kong
Prior art keywords
promoter
lymphocyte
blood cell
application
introducing gene
Prior art date
Application number
HK11100473.3A
Other languages
English (en)
Inventor
Masaya Takemoto
Yasuko Mori
Koichi Yamanishi
Isao Fuke
Yasuyuki Gomi
Michiaki Takahashi
Original Assignee
Univ Osaka Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Osaka Res Found filed Critical Univ Osaka Res Found
Publication of HK1146299A1 publication Critical patent/HK1146299A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16511—Roseolovirus, e.g. human herpesvirus 6, 7
    • C12N2710/16522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK11100473.3A 2005-09-08 2011-01-18 Promoter for introducing gene into lymphocyte or blood cell and application thereof HK1146299A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005261366 2005-09-08

Publications (1)

Publication Number Publication Date
HK1146299A1 true HK1146299A1 (en) 2011-05-27

Family

ID=37835831

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11100473.3A HK1146299A1 (en) 2005-09-08 2011-01-18 Promoter for introducing gene into lymphocyte or blood cell and application thereof

Country Status (9)

Country Link
US (3) US8008467B2 (xx)
EP (3) EP2368986A1 (xx)
JP (3) JPWO2007029712A1 (xx)
KR (3) KR101354995B1 (xx)
CN (3) CN101300350A (xx)
AU (1) AU2006288279A1 (xx)
CA (3) CA2621917A1 (xx)
HK (1) HK1146299A1 (xx)
WO (1) WO2007029712A1 (xx)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120220028A1 (en) * 2009-09-04 2012-08-30 The Research Foundation For Microbial Diseases Of Osaka University Enhancer for promoter, and use thereof
CN101869715A (zh) * 2010-05-26 2010-10-27 江苏命码生物科技有限公司 载有干扰核糖核酸的细胞微粒子、其制备方法及其应用
SG191246A1 (en) * 2010-12-24 2013-07-31 Agency Science Tech & Res Modified human cmv promoters that are resistant to gene silencing
US10365597B2 (en) * 2016-05-26 2019-07-30 Xerox Corporation Endless belt comprising boron nitride nanotubes
CN106086011B (zh) * 2016-06-18 2019-10-18 北京大北农科技集团股份有限公司 用于检测除草剂耐受性大豆植物dbn9004的核酸序列及其检测方法
WO2023147604A2 (en) * 2022-01-31 2023-08-03 Trames Bio, Inc. Expression cassettes for treating epilepsy and neuropathic pain
KR102509175B1 (ko) 2022-10-11 2023-03-15 주식회사 하이플랜 화재확산방지기능을 갖는 배전반

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
WO1985000817A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of interleukin ii
US5879936A (en) 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
GB9323404D0 (en) * 1993-11-12 1994-01-05 Smithkline Beecham Plc Pharmaceuticals
CN1111069C (zh) * 1999-07-13 2003-06-11 暨南大学 Hhv8的mip同源物在防治艾滋病的药物中的应用
GB0027088D0 (en) * 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
EP1681346A4 (en) * 2003-08-29 2006-11-02 Soiken Inc HHV-6 OR HHV-7 DERIVED RECOMBINANT VIRUS VECTOR, METHOD FOR THE PRODUCTION THEREOF, METHOD FOR TRANSFORMING A HOST CELL USING THEREOF, TRANSFORMED HOST CELL AND GENE THERAPY METHOD USING THEREOF
GB0400965D0 (en) * 2004-01-16 2004-02-18 Glaxo Group Ltd Promoter

Also Published As

Publication number Publication date
CN102174515A (zh) 2011-09-07
CA2621917A1 (en) 2007-03-15
KR20110102962A (ko) 2011-09-19
CA2808659A1 (en) 2007-03-15
JP5513467B2 (ja) 2014-06-04
JP2012040022A (ja) 2012-03-01
EP1932911A4 (en) 2009-10-28
US20090208516A1 (en) 2009-08-20
KR101354996B1 (ko) 2014-02-03
WO2007029712A1 (ja) 2007-03-15
KR101354994B1 (ko) 2014-01-23
US8013140B2 (en) 2011-09-06
US8013139B2 (en) 2011-09-06
CN101906418B (zh) 2013-06-12
KR101354995B1 (ko) 2014-01-23
EP2368986A1 (en) 2011-09-28
JP2012065663A (ja) 2012-04-05
US20090214579A1 (en) 2009-08-27
EP1932911A1 (en) 2008-06-18
EP2434013A1 (en) 2012-03-28
KR20080036244A (ko) 2008-04-25
CA2808179A1 (en) 2007-03-15
CN101300350A (zh) 2008-11-05
AU2006288279A1 (en) 2007-03-15
CN101906418A (zh) 2010-12-08
US20100005536A1 (en) 2010-01-07
JPWO2007029712A1 (ja) 2009-03-19
US8008467B2 (en) 2011-08-30
KR20110100326A (ko) 2011-09-09
JP5513468B2 (ja) 2014-06-04

Similar Documents

Publication Publication Date Title
HK1146299A1 (en) Promoter for introducing gene into lymphocyte or blood cell and application thereof
BR112014007852A2 (pt) nucleosídeos, nucleotídeos e ácidos nucleicos modificados e usos dos mesmos
BR112012012912A2 (pt) anticorpo ou fragmento do mesmo, ácido nucleico, vetor, célula hospedeira, método para a produção de um anticorpo ou um fragmento do mesmo, composição farmacêutica, método para tratar ou prevenir uma condição médica em um indivíduo, uso de um anticorpo ou fragmento do mesmo e métodos in vitro para neutralizar il-10 em uma amostra e para detectar a presença de il-10 em uma amostra.
WO2012019168A3 (en) Engineered nucleic acids and methods of use thereof
WO2013039861A3 (en) Engineered nucleic acids and methods of use thereof
BR112015016005A2 (pt) preparação de amostra em um suporte sólido
EA201100001A3 (ru) Нуклеотиды и нуклеозиды и методы их использования в секвенировании днк
BR112015008708A2 (pt) composição para clivagem de dna alvo compreendendo um rna guia específico para o dna alvo e ácido nucleico que codifica proteína cas ou proteína cas e uso da mesma
WO2012045082A3 (en) Engineered nucleic acids and methods of use thereof
BR112013025758A2 (pt) monitoramento de misturas de amplificação de recombinase polimerase
BR112014005543A2 (pt) sistema de descarte de medicação geral
WO2019144126A8 (en) Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells
EP2521587A4 (en) RELEASE SYSTEM
MX2010009331A (es) Dispositivo para la separacion de plasma.
WO2011072247A8 (en) Pathogen restriction factors
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
BR112013033462A2 (pt) método para a redução de complexidade do genoma e detecção de polimorfismo
BR112013024809A2 (pt) tratamento para infecção com vírus de hepatite b sozinho ou em combinação com vírus de hepatite delta e doenças do fígado associadas
BR112014002173A2 (pt) proteínas purificadas
BR112014006511A2 (pt) atividade de dnase endógena para reduzir teor de dna
BRPI0813691A2 (pt) Sistema bicomponente ou multicomponente de cura por meio de um sistema iniciador redox e com uma vida útil(pot life) controlável e também seu uso
WO2010062742A3 (en) Methods for freparation and use of marrow infiltrating lymphocytes (mils)
DK1463809T3 (da) Mutation af DNA-polymeraser fra arkebakterier
BR112012014624A8 (pt) suspensão homogênea de compostos de imunopotenciação e usos dos destes
BR112015022641A2 (pt) construção de dna, célula hospedeira eucariótica, linhagem de células eucarióticas e processo de preparação de uma proteína-alvo

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170905